Pioneering work by Braak and Braak in post‐mortem AD samples (Braak & Braak, 1991), and more recent studies in living patients via positron emission tomography (PET) (Hoenig et al., 2018), demonstrated that tau pathology targets brain regions in a stereotypical temporal sequence correlating with cognitive decline in AD (Braak, Alafuzoff, Arzberger, Kretzschmar, & Tredici, 2006). The gene discussed is MAPT; the disease is Mental deterioration.